Lecithin: Cholesterol acyltransfer, dyslipoproteinaemia and membrane lipids in uraemia

Journal of Nephrology

Volumn 14, Issue 6, 2001, Pages 472-480

  Gillett, Michael P T ^a   Obineche, Enyioma N ^a   El Rokhaimi, Mona ^a   Lakhani, Mohamed S ^a   Abdulle, Abdishakur ^a   Sulaiman, Mustapha ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Cholesterol; Cholesteryl esters; Erythrocytes; Lipoproteins; Lympho cytes; Membranes; Phospholipids; Triacylglycerols

Indexed keywords

CHOLESTEROL; CHOLESTEROL ESTER; CREATININE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; MEMBRANE LIPID; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID; UREA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CELL LEVEL; CELL MEMBRANE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIALYSIS; DIET RESTRICTION; DISEASE COURSE; DYSLIPOPROTEINEMIA; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HEMODIALYSIS; HUMAN; HUMAN CELL; LIPID ANALYSIS; LIPOLYSIS; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; MORBIDITY; MORTALITY; NORMAL VALUE; PERITONEAL DIALYSIS; PLASMA; PROTEIN SECRETION; UREMIA;

ADULT; ERYTHROCYTES; FEMALE; HUMANS; HYPERLIPIDEMIAS; KIDNEY FAILURE, CHRONIC; LIPIDS; LYMPHOCYTES; MALE; MEMBRANE LIPIDS; MIDDLE AGED; PERITONEAL DIALYSIS; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; REFERENCE VALUES; RENAL DIALYSIS; UREMIA;

EID: 0035717260     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Lipoprotein metabolism in renal failure
2. Hyperlipidemia in patients with chronic renal disease
3. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here?
4. Importance of hyperlipidaemia and therapy in renal patients
5. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity
6. Albumin synthesis, albuminuria and hyperlipidemia in nephrotic patients
7. Pattern of hyperlipoproteinemia in human nephritic syndrome: Influence of renal failure and diabetes mellitus
8. Lipid abnormalities in the nephritic syndrome: Causes, consequences and treatment
9. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure
10. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis
11. Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients
12. Abnormalities in lipoprotein metabolism in hemodialysis patients
13. Impaired high density lipoprotein metabolism in uremic patients
14. Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias
15. Apolipoprotein B turnover in dialysis patients: Its relationship to pathogenesis of hyperlipidemia
16. Decreased clearance of low-density lipoprotein in uremic patients under dialysis treatment
17. Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients
18. Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia
19. Lecithin: Cholesterol acyltransferase activity, HDL-cholesterol and apolipoprotein A in serum of patients undergoing chronic haemodialysis
20. Plasma lecithin-cholesterol acyltransferase activities in uraemic patients
21. Lecithin: Cholesterol acyltransferase activity in dialyzed and undialyzed chronic uremic patients
22. Plasma lipoproteins and lecithin: Cholesterol acyltransferase distribution in patients on dialysis
23. Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis
24. Decreased plasma lecithin: Cholesterol acyltransfer and associated changes in plasma and red cell lipids in uraemia
25. Physiological role of lecithin-cholesterol acyltransferase
26. The metabolic role of lecithin: Cholesterol acyltransferase: Perspectives from pathology
27. Effect of treatment with simvastatin on serum cholestryl ester transfer in patients on dialysis
28. A simple method for isolation and purification of total lipids from animal tissues
29. Plasma concentrations of lysolecithin and other phospholipids in the healthy population and in men suffering from atherosclerotic disease
30. Fractionation of cholesterol esters by thin layer chromatography
31. Protein measurement with the Folin phenol reagent
32. Cholesterol esterifying enzymes - Lecithin: Cholesterol acyltransferase (LCAT) and acylcoenzymeA: Cholesterol acyltransferase (ACAT)
33. Familial serum cholesterol ester deficiency. Clinical study of a patient with a new syndrome
34. Familial plasma cholesterol ester deficiency. Clinical studies of a family
35. Familial lecithin: Cholesterol acyltransferase deficiency complicated with unconjugated hyperbilirubinemia and peripheral neuropathy. The first reported cases in the Far East
36. Familial LCAT deficiency. Report of two patients from a Canadian family of Italian and Swedish descent
37. Lecithin: Cholesterol acyltransferase deficiency and cell membrane lipids and function in human liver disease
38. Familial lecithin: Cholesterol acyltransferase deficiency - A clinical survey
39. The effect of insulin and hypocaloric diet on LCAT activity in type 2 diabetes
40. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients
41. Recent advances in statins and the kidney
42. Familial plasma cholesterol ester deficiency. A study of the erythrocytes
43. Familial lecithin: Cholesterol acyltransferase deficiency. Studies on lipid composition and morphology of tissues
44. Familial lecithin: Cholesterol acyltransferase deficiency. Ultrastructural studies on lipid deposition and tissue reactions
45. Membrane lipid changes in erythrocytes, liver and kidney in acute and chronic experimental liver disease in rats
46. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease